Active ingredient: Dobutamine - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

• Cardiotonic Agents
• Sympathomimetic

Dosage Forms

• Liquid

Brands / Synonyms

Dobutamina [Inn-Spanish]; Dobutamine; Dobutamine Hcl; Dobutamine Hcl in Dextrose 5%; Dobutamine Hydrochloride; Dobutamine [Usan:Ban:Inn]; Dobutamine [Usan]; Dobutaminum [Inn-Latin]; Dobutrex; Inotrex; Racemic-Dobutamine

Indications

For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures

Pharmacology

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

Mechanism of Action

Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Not Available

Contraindications

Dobutamine is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine.

Drug Interactions

Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug. In such a case, the peripheral vascular resistance may increase.

Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.

There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.